Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs - something Roche (ROG.S) aims to leverage, for example, with last month’s $2 billion purchase of Flatiron Health.
SUBSCRIBE
Biohealth Innovation
Founding Member of
